Saturday, June 3, 2023, Chicago, Illinois, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time)

Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate Cancer

A CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Emmanuel S Antonarakis, MD
Clark Endowed Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Prof Karim Fizazi, MD, PhD
Head of Service and Full Professor
Institut Gustave Roussy
University of Paris Saclay
Villejuif, France

Rana R McKay, MD
Associate Professor of Medicine and Urology
Associate Director, Translational Sciences
Co-Lead, Genitourinary Oncology Program
University of California San Diego
Moores Cancer Center
La Jolla, California


Alicia K Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts

A Oliver Sartor, MD
Director of Radiopharmaceutical Clinical Trials
Professor, Department of Oncology
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Current Management of Nonmetastatic Prostate Cancer — Dr Morgans

  • Current indications for androgen deprivation therapy (ADT) alone or in combination with radiation therapy after prostatectomy for localized prostate cancer
  • Key findings from the STAMPEDE trial evaluating the efficacy and safety of abiraterone and prednisolone with or without enzalutamide and ADT for high-risk nonmetastatic prostate cancer; current and potential roles
  • Design, eligibility criteria and major efficacy and safety results from the Phase III PRESTO trial evaluating the role of ADT intensification with apalutamide with or without abiraterone and prednisone for biochemically recurrent prostate cancer; potential implications
  • Recently presented results from the Phase III EMBARK trial of enzalutamide/leuprolide and enzalutamide monotherapy for patients with high-risk, nonmetastatic, hormone-sensitive prostate cancer who experience a rising PSA after local therapy
  • Published efficacy and safety findings from Phase III trials documenting the effectiveness of enzalutamide, apalutamide and darolutamide for nonmetastatic castration-resistant prostate cancer (CRPC)
  • Clinical, biological and practical factors guiding the selection of enzalutamide, apalutamide and darolutamide for nonmetastatic CRPC

MODULE 2: New Considerations in Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Prof Fizazi

  • Practical, disease-specific and patient-specific factors contributing to the choice of therapy for mHSPC
  • Long-term follow-up from Phase III trials leading to the approvals of docetaxel, abiraterone, enzalutamide and apalutamide in combination with ADT for mHSPC
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III PEACE-1 study of ADT and docetaxel with or without local radiation therapy with or without abiraterone and prednisone for mHSPC
  • Rationale for, design of and published efficacy and safety findings from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC
  • FDA approval of darolutamide in combination with docetaxel/ADT and optimal incorporation into current management algorithms
  • Ongoing Phase III trials, such as TALAPRO-3, CYCLONE 3, PSMAddition and CAPItello-281, that are attempting to further define the optimal management of mHSPC

MODULE 3: Available and Emerging Strategies for Newly Diagnosed Metastatic CRPC (mCRPC) — Dr McKay

  • Key clinical and biological factors in the selection of therapy for newly diagnosed mCRPC; influence of earlier use of secondary hormonal therapy and chemotherapy on current management approaches
  • Key findings from clinical trial and real-world data sets exploring the efficacy and safety of sipuleucel-T
  • Optimal patient selection for treatment with sipuleucel-T; importance of early identification of appropriate candidates
  • Data sets defining the role of secondary hormonal therapies for patients with mCRPC, including those who have received one of these agents in an earlier disease setting
  • Role of the CDK4/6 pathway in prostate cancer proliferation and resistance to androgen receptor (AR)-targeted therapy
  • Available efficacy and safety findings with CDK4/6 inhibitors for mCRPC
  • Design, eligibility criteria and primary and secondary endpoints of the Phase II/III CYCLONE 2 trial evaluating first-line abiraterone and prednisone with or without abemaciclib for mCRPC

MODULE 4: Identification and Management of mCRPC with a Homologous Recombination Repair (HRR) Gene Abnormality — Dr Antonarakis

  • Incidence of BRCA1/2 and other HRR abnormalities, such as ATM, PALB2 and CDK12, in patients with prostate cancer
  • Mechanistic similarities and differences among approved (eg, olaparib, rucaparib) and investigational (eg, talazoparib, niraparib) PARP inhibitors with documented activity in mCRPC; implications for efficacy and tolerability
  • Published data sets with PARP inhibitor monotherapy for patients with mCRPC (eg, from the PROfound, TRITON2, TRITON3, GALAHAD and TALAPRO-1 trials)
  • FDA-approved indications for olaparib and rucaparib monotherapy for mCRPC and optimal integration into current management algorithms
  • Key findings among patients with and without HRR abnormalities from the Phase III PROpel, MAGNITUDE and TALAPRO-2 trials combining olaparib and abiraterone, niraparib and abiraterone and talazoparib and enzalutamide, respectively, in the first-line setting
  • Potential role of PARP inhibitors in combination with AR-targeted therapy for patients with mCRPC; implications of the recent Oncologic Drugs Advisory Committee recommendation to limit potential FDA approval of olaparib/abiraterone to patients with BRCA mutations

MODULE 5: Management of Progressive mCRPC — Dr Sartor

  • Published research findings with, optimal clinical use of and ongoing evaluation of radium-223 chloride
  • Key efficacy and safety findings with lutetium Lu 177 vipivotide tetraxetan for progressive, PSMA-positive mCRPC
  • FDA approval of lutetium Lu 177 vipivotide tetraxetan and optimal incorporation into current management algorithms
  • Design, eligibility criteria and emerging findings from the Phase III PSMAfore study comparing lutetium Lu 177 vipivotide tetraxetan to a change in AR pathway inhibitor for patients with PSMA-positive mCRPC
  • Major efficacy and safety findings from clinical research studies evaluating the optimal use of cabazitaxel for mCRPC
  • Appropriate integration of cabazitaxel into current mCRPC treatment algorithms and practical considerations with its use
  • Other novel agents and strategies under investigation for mCRPC

Target Audience
This activity is intended for medical and radiation oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise published research and current guideline recommendations on the optimal management of biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
  • Explore available data with treatment intensification using cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of therapeutic options for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess available research with PARP inhibitors alone or in combination with secondary hormonal therapies for mCRPC, and discern how to optimally incorporate these agents and regimens into the clinical management algorithm.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Antonarakis — Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Sanofi, Tempus; Consulting Agreements: Aadi Bioscience, AIkido Pharma Inc, Blue Earth Diagnostics, CM Propel, Corcept Therapeutics, EcoR1 Capital LLC, Foundation Medicine, HOOKIPA Pharma Inc, KeyQuest Health, MacroGenics Inc, Menarini Silicon Biosystems, z-Alpha; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Constellation Pharmaceuticals, Merck, Orion Corporation, Sanofi; Patent Holder: QIAGEN; Nonrelevant Financial Relationship: European Association of Urology (UROwebinar), Ismar Healthcare NV. Prof Fizazi — Advisory Committee: Arvinas, CureVac, Orion Corporation; Data and Safety Monitoring Board/Committee: Lilly; Consulting Agreements (with My Institution): Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Sanofi. Dr McKay — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Caris Life Sciences, Dendreon Pharmaceuticals Inc, Exelixis Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Oncternal Therapeutics, Tempus. Dr Morgans — Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Foundation Medicine, Janssen Biotech Inc, Lantheus, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi, Telix Pharmaceuticals Limited; Contracted Research: Bayer HealthCare Pharmaceuticals, Myovant Sciences, Pfizer Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc. Dr Sartor — Consultant: Advanced Accelerator Applications, Amgen Inc, ARTbio, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Convergent Therapeutics Inc, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Foundation Medicine, Fusion Pharmaceuticals, Genzyme Corporation, Hengrui Therapeutics Inc, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Morphimmune, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, NorthStar Rx LLC, Novartis, Noxopharm, Pfizer Inc, POINT Biopharma, Progenics Pharmaceuticals Inc, Ratio Therapeutics, Sanofi, Telix Pharmaceuticals Limited, TeneoBio, Tessa Therapeutics, Theragnostics, z-Alpha; Equity Interests: Telix Pharmaceuticals Limited; Grant/Research Support: Advanced Accelerator Applications, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Invitae, Janssen Biotech Inc, Lantheus, Merck, Novartis, Progenics Pharmaceuticals Inc, TeneoBio; Nonrelevant Financial Relationship: Ratio Therapeutics.

CONTRIBUTING CLINICAL INVESTIGATORS — Neeraj Agarwal, MD, FASCO — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Calithera Biosciences, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Janssen Biotech Inc, Lilly, Lumos Pharma, Medivation Inc, a Pfizer Company, Merck, Nektar, Novartis, Pfizer Inc, Prometheus Laboratories Inc, Rexahn Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc, TRACON Pharmaceuticals Inc. David S Morris, MD — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Pfizer Inc; Contracted Research: Clovis Oncology, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Pfizer Inc. Sandy Srinivas, MD — Advisory Committee and Consulting Agreements: Janssen Biotech Inc, Merck, Novartis, Seagen Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Exelixis Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.

​ There is no fee to participate in this hybrid event. For the in-person symposium in Chicago, preregistration is required as seating is limited.
​
IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:00 PM Central Time on Saturday, June 3. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.